Coegin Pharma will provide a new generation of therapeutics treating serious medical conditions associated with chronic inflammatory disorders and specific cancers.
Due to COVID-19, no upcoming events are scheduled.
All of Coegin Pharma’s small molecules are nanomolar potent drug candidates targeting chronic inflammatory disorders and cancers with high unmet need. The individual compounds represent a series of international drug discovery efforts conducted in collaboration with key leaders in the field
Coegin Pharma is a global leader in understanding the role of an intracellular target downstream of the classical therapeutic intervention of the pro-inflammatory cascade activated by NFkB. Coegin Pharma’s small molecules inhibits the group IVA cPLA2 enzyme, however still allowing the cell to function at the physiological level.
Coegin Pharma presents the newest paper published in a scientific journal with the title “Detection and Differentiation of Breast Cancer Sub-Types using a cPLA2α Activatable Fluorophore.”, published in Scientific Reports, April 2019.